SWI/SNF mutations lead to thyroid dedifferentiation and tumor progression, while the loss of SWI/SNF promotes resistance to RAF/MEK inhibitor-based redifferentiation therapies in TC [31]. This evidence concerns the gene MAP2K7 and neoplasm.